| Today's Top Story |  |  | | - Medivation-Astellas prostate cancer drug Xtandi wins FDA approval
The FDA approved Medivation and Astellas Pharma's Xtandi, or enzalutamide, to treat men whose prostate cancer spreads despite hormone therapy and chemotherapy. Xtandi is an androgen inhibitor designed to prevent testosterone from binding to prostate cancer cells. Medivation plans to bring the drug to market this month. Reuters (8/31)        | HEALTHY CASH FLOW SOLUTIONS FOR YOUR BUSINESS
The Enhanced Plum Card from American Express OPEN®
Flexible Payment Terms:
• Get a 1.5% Early Pay Discount
• Take up to 60 Days to Pay with No Interest
Limited Time Offer: Get up to a 2% Discount: 1.5% Early Pay Discount plus, for the first 6 months, get an extra 0.5% on purchases†.
LEARN MORE †Terms and Restrictions Apply. |
  | Health Care & Policy | | | | - FTC clears Spectrum's $206M buyout of Allos
The Federal Trade Commission gave Spectrum Pharmaceuticals approval to acquire oncological drugmaker Allos Therapeutics for $206 million. The deal would give Spectrum rights to Allos' Folotyn, a drug for relapsed or refractory peripheral T-cell lymphoma that generated about $50 million in sales last year. Spectrum hopes to finalize the agreement early this month. Reuters (8/31) - Pfizer licenses potential cancer drug to VLST
VLST secured exclusive rights to Pfizer's CP-870,893, an anti-CD40 monoclonal antibody whose safety and maximum tolerated dose was established in several preclinical and clinical studies. In exchange, Pfizer acquired a 5% stake in VLST and keeps co-exclusive rights to the compound in oncology vaccination. VLST plans to take the antibody "into efficacy studies in an oncology setting." PharmaTimes (U.K.) (9/3) | Company & Financial News | | | | | Global Developments | | | | - Life Tech signs global distribution deal with Chinese firm
Life Technologies agreed to distribute Sino Biological's recombinant proteins, antibodies and other products globally under joint brands. The firms also agreed to develop new products. "Through this collaboration, we plan to leverage our strong brands, worldwide commercial reach and technology support with Sino Biological's world leading technologies to develop solutions for scientists worldwide who are tackling important health care challenges such as cancer, diabetes and heart disease," said Life Technologies Chairman and CEO Gregory T. Lucier. China Daily (Beijing) (9/1)
| Food & Agriculture | | | | | Industrial & Environmental | | | | - Green chemicals from yeast
Verdezyne has piloted greener, cheaper production of adipic acid -- used to make nylon 6,6 for clothes, carpet and industrial applications -- with yeast and byproducts from vegetable oil production. Adipic acid usually is made through petroleum processes. The firm is also using yeast to produce other products, such as ethanol from cellulosic feedstocks. North County Times (Temecula, Calif.) (8/30) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | The best people possess a feeling for beauty, the courage to take risks, the discipline to tell the truth, the capacity for sacrifice."
--Ernest Hemingway,
American author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, August 31, 2012
- Thursday, August 30, 2012
- Wednesday, August 29, 2012
- Tuesday, August 28, 2012
- Monday, August 27, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment